Bausch Health Has Full Plate While Trimming Debt, Setting Table For Bausch + Lomb Separation
With Decision Pending On Spinout Method, SEC Form For IPO Filed
Bausch Health says it’s continuing a recovery from the disaster previous management left, when the firm operated as Valeant Pharmaceuticals, even though it reported a $595m net loss for Q2. “We've been trying to solve this debt issue for the company,” says CEO Joseph Papa.
